hotspot -WSS

hotspot

author：comprehensive 2025-10-02 22:40:31 - browse：9696

Adam's take main illustration — Molly Ferguson/STAT

Hello! Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale.

Gilead needs Arcellx more than ever

The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business. Strategically, does it make sense for Gilead to invest even more in antibody-drug conjugates like Trodelvy, where its lackluster profile and increased competition overall makes winning seem unlikely? Or, should Gilead double down on its Kite division and CAR-T cell therapy — the type of cancer treatments where it truly excels?

If the answers to those questions are no and yes (I lean that way), then Gilead’s current partnership with Arcellx, which is developing a BCMA-targeted CAR-T therapy for multiple myeloma, becomes a lot more important.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： What should King Charles tell the public about his cancer?

WSS

KalVista pill reduced swelling 'attacks' caused by genetic disease

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

Private equity deals in Medicare Advantage declines

Gilead might be held responsible for not developing a drug

How to fix the rural physician shortage in the U.S.

The dental labor crisis is a moment of opportunity

entertainment

hotspot

Gilead needs Arcellx more than ever

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Biotech companies concerned about China biosecurity crackdown

Anesthesiologist group: stop taking Ozempic before surgery

RaDonda Vaught to speak at CommonSpirit event on patient safety

Medical leaders decry Supreme Court decision on affirmative action

A disappointing year of Humira biosimilars

The high cost of giving birth even with insurance

An inside look at PIPEs, biotech's buzzy new financing tool

New air purifier tech could be key to improving indoor air quality

What should King Charles tell the public about his cancer?

hotspot

RSV vaccines may be linked to small increased risk of developing GBS

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

Biogen Alzheimer’s drug launch off to slow start

Why getting cancer drugs just got harder for rural patients

Gilead might be held responsible for not developing a drug

PhRMA lawsuit over Medicare drug price negotiation tossed

entertainment

hotspot

leisure time

hotspot